BRD2 and neoplasm: Studies using Signatera during NAT reported a 94.7% association of ctDNA clearance and decrease in tumor volume in TNBC and a 100% association of ctDNA clearance and CR in HR+/HER2-, TNBC and HER2+ patients [69,71].